Skip to main navigation Skip to search Skip to main content

Exploiting temozolomide-induced hypermutation with pembrolizumab in a refractory high-grade neuroendocrine neoplasm: A proof-of-concept case

  • Samuel J. Klempner
  • , Andrew Hendifar
  • , Kevin M. Waters
  • , Nicholas Nissen
  • , Eric Vail
  • , Richard Tuli
  • , Alain Mita

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)614-619
Number of pages6
JournalJCO Precision Oncology
Volume4
DOIs
StatePublished - 2020
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this